Date published: 2025-11-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

OR52B6 Inhibitors

OR52B6 inhibitors are a class of chemical compounds specifically designed to target and modulate the activity of the OR52B6 receptor, a member of the olfactory receptor family within the broader G-protein-coupled receptor (GPCR) superfamily. Although olfactory receptors, including OR52B6, are primarily recognized for their role in detecting odor molecules, they are also expressed in various non-olfactory tissues, suggesting they may have additional roles in different physiological contexts. OR52B6 inhibitors function by binding to the receptor, thereby blocking or altering its interaction with its natural ligands. This inhibition can lead to changes in the signaling pathways regulated by OR52B6, which may influence a variety of cellular processes. Research into OR52B6 inhibitors is focused on understanding the receptor's broader biological functions, particularly in non-olfactory systems where its role is less clearly defined. The chemical diversity of OR52B6 inhibitors is broad, with different compounds exhibiting varying degrees of specificity, potency, and modes of action. Some of these inhibitors act as competitive antagonists, binding directly to the active site of OR52B6 and preventing natural ligands from activating the receptor. Others may function as allosteric inhibitors, binding to different sites on the receptor and inducing conformational changes that reduce its activity or alter its signaling profile. The design and development of OR52B6 inhibitors typically involve the use of advanced structural biology techniques, such as X-ray crystallography, cryo-electron microscopy, and molecular modeling. These techniques are essential for identifying key binding sites on the receptor and optimizing the interactions between the inhibitor and OR52B6. Researchers aim to create inhibitors that are highly selective for OR52B6, ensuring that they effectively target the receptor without affecting other GPCRs or unrelated proteins. By studying these inhibitors, scientists can gain deeper insights into the functional roles of OR52B6 in various biological systems and how its activity can be modulated to influence specific cellular processes.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Trichostatin A, by inhibiting histone deacetylase, could lead to hyperacetylation of histones, potentially resulting in the downregulation of OR52B6 by modifying the chromatin structure associated with its gene promoter.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

5-Azacytidine may incorporate into the OR52B6 gene sequence and competitively inhibit DNA methyltransferases, leading to DNA demethylation and a consequent decrease in OR52B6 expression due to changes in the transcriptional activity of its promoter.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

Suberoylanilide Hydroxamic Acid (Vorinostat) could decrease OR52B6 expression by specifically altering histone acetylation patterns, thereby changing the accessibility of transcriptional machinery to the OR52B6 gene locus.

Mithramycin A

18378-89-7sc-200909
1 mg
$54.00
6
(1)

Mithramycin A might bind selectively to the GC-rich regions in the promoter of the OR52B6 gene, potentially inhibiting the binding of specific transcription factors necessary for OR52B6 transcription initiation.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

Actinomycin D has the potential to intercalate between DNA base pairs at the OR52B6 gene, obstructing RNA polymerase action and consequently leading to a reduction in OR52B6 mRNA synthesis.

RG 108

48208-26-0sc-204235
sc-204235A
10 mg
50 mg
$128.00
$505.00
2
(1)

RG 108 may target DNA methyltransferases, possibly preventing the methylation of the OR52B6 promoter. This could result in an upsurge in transcriptional activity and a subsequent decrease in OR52B6 expression.

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$214.00
$316.00
$418.00
7
(1)

5-Aza-2′-Deoxycytidine (Decitabine) could lead to the hypomethylation of cytosine bases within the OR52B6 promoter region, which might reduce the transcriptional repression mechanisms, culminating in decreased expression of OR52B6.

MS-275

209783-80-2sc-279455
sc-279455A
sc-279455B
1 mg
5 mg
25 mg
$24.00
$88.00
$208.00
24
(2)

MS-275 (Entinostat), as a selective inhibitor of class I histone deacetylases, might lead to an open chromatin conformation at the OR52B6 locus, potentially reducing the expression levels of the OR52B6 gene.

Romidepsin

128517-07-7sc-364603
sc-364603A
1 mg
5 mg
$214.00
$622.00
1
(1)

Romidepsin, by inhibiting histone deacetylase, could induce hyperacetylation of histones at the OR52B6 gene, potentially leading to the suppression of its transcriptional activity.

Sodium Butyrate

156-54-7sc-202341
sc-202341B
sc-202341A
sc-202341C
250 mg
5 g
25 g
500 g
$30.00
$46.00
$82.00
$218.00
19
(3)

Sodium butyrate, by inhibiting histone deacetylase, could hyperacetylate the histones associated with the OR52B6 gene, potentially disrupting the compact chromatin structure and leading to a subsequent downregulation of OR52B6 expression.